

# SECOND SUPPLEMENTARY BIDDER'S STATEMENT

in respect of the Offer by  
**RHINOMED HEALTH CORPORATION**  
to acquire all of the ordinary shares in  
**RHINOMED LIMITED**

# ACCEPT NOW

---

## 1 INTRODUCTION

This document relates to the Offer by Rhinomed Health Corporation (the **Bidder**), an entity wholly owned by William Whitney George (**Whitney George**), to acquire all your fully paid ordinary shares in Rhinomed Limited (ACN 107 903 159) (**Rhinomed**) for the option of either:

- (a) 4 cents cash per Rhinomed Share; or
- (b) 1 newly issued and fully paid common share of the Bidder for each Rhinomed Share.

This is the second supplementary bidder's statement under section 643(1) of the Corporations Act 2001 (Cth) (**Corporations Act**) issued by the Bidder in relation to its off-market takeover offer for all the shares in Rhinomed Limited (the **Offer**). It supplements and should be read together with the bidder's statement contained in the Takeover Booklet dated 2 June 2025 (**Takeover Booklet**)<sup>1</sup> and the first supplementary bidder's statement dated 20 June 2025 (**First Supplementary Bidder's Statement**), both of which are available at <https://www.rhinomed.global/investor-information/>.

This supplementary bidder's statement is dated and was lodged with Australian Securities and Investments Commission (**ASIC**) on 30 June 2025. Neither ASIC nor any of its respective officers take any responsibility for its contents.

## 2 UPDATE ON THE 90% MINIMUM RELEVANT INTEREST CONDITION

The Offer is conditional on the Bidder and its Associates, at or before the end of the Offer Period, having Relevant Interests in such number of Rhinomed Shares which represent at least 90% of all of the Rhinomed Shares (on a fully diluted basis) (**90% Condition**).

Based on acceptances as at the date of this document, the Bidder and its Associates now have a combined Relevant Interest in approximately 53.78% of the Rhinomed Shares on issue<sup>2</sup> and expects this to increase to approximately 85% once all Rhinomed Directors Accept the Offer.<sup>3</sup> The Bidder reserves its rights to waive this condition.

You should **ACCEPT THE OFFER** immediately for the following reasons:

- If the Bidder determines to waive the 90% Condition, it will:

---

<sup>1</sup> Capitalised but undefined terms used in this document have the meaning given to them in the Takeover Booklet.

<sup>2</sup> Based on acceptances of the Offer received up to 10am (AEST) on 30 June 2025.

<sup>3</sup> The Rhinomed Directors collectively hold approximately 34% of the Rhinomed Shares on issue and indicated in the Takeover Booklet that they intend to accept the Offer after 26 June 2025.

- be able to unilaterally pass ordinary shareholder resolutions that it is entitled to vote on, as such resolutions require a simple majority to be approved (being more than 50%) and the Bidder would control approximately 53.78% of the votes; and
- be able to reconstitute the Rhinomed Board with directors solely appointed by it, thereby having significant influence and control over the future direction of Rhinomed; and
- implement its remaining intentions for Rhinomed as a partly owned but controlled entity as set out in section 3.6(c) of the Takeover Booklet;
- no superior proposal has arisen and a superior proposal from another bidder is now unlikely to arise, given the Relevant Interest that the Bidder has; and
- your Rhinomed Shares may be acquired under compulsory acquisition if the Bidder reaches a Relevant Interest of 90%. If your Rhinomed Shares are acquired under compulsory acquisition, you will likely be delayed in receiving your consideration compared to if you had accepted the Offer.

### 3 HOW TO ACCEPT THE OFFER

The easiest way to accept the Offer is online by visiting <https://investor.automic.com.au/#/signup> and following the prompts. You can also accept by using the physical Acceptance Form that you should have received with the Takeover Booklet (and that is accessible for download and printing from <https://investor.automic.com.au/#/signup>).

If you require assistance with your acceptance, please call the Rhinomed Shareholder Information Line on 1300 441 599 (within Australia) or +61 2 9068 1927 (outside Australia) between 8:30am and 7:00pm Monday to Friday (excluding public holidays).

### 4 EXTENSION OF OFFER PERIOD

The Offer Period has been extended to **5.00pm (Sydney time) on Monday 14 July 2025**. You should accept the Offer without delay before this time. The Bidder reserves its right to extend the Offer Period in accordance with the Corporations Act.

A notice to extend the Offer Period is included at the end of this document.

### 5 APPROVAL

This Supplementary Bidder's Statement, and the notice to extend the Offer Period included on the following page, has been approved by a resolution passed by the sole director of the Bidder.

Signed for and on behalf of **Rhinomed Health Corporation**.



**William Whitney George**

Director

## Notice of Variation of Offer – Extension of Offer Period

To: Australian Securities and Investments Commission (**ASIC**)

Rhinomed Limited

Each Rhinomed shareholder and other person referred to in sections 650D(1)(c) and 650D(2) of the Corporations Act 2001 (Cth) (as modified by ASIC Class Order [13/521]) (**Corporations Act**)

Rhinomed Health Corporation (**Bidder**) gives this notice in relation to its off-market takeover bid for all of the ordinary shares in Rhinomed Limited (ACN 107 903 159) (**Rhinomed**), the terms of which are set out in the bidder's statement contained within the Takeover Booklet dated 2 June 2025 (**Takeover Booklet**), as supplemented by the First Supplementary Bidder's Statement dated 20 June 2025 and the Second Supplementary Bidder's Statement dated 30 June 2025 (**Bidder's Statement**) (the **Offer**). Unless otherwise defined, capitalised terms in this notice have the same meaning given in the Takeover Booklet.

### 1 Variation of Offer - Extension of Offer Period

The Bidder gives notice under section 650D(1) of the Corporations Act that, pursuant to section 650C(1) of the Corporations Act, the Offer is varied by:

- (a) extending the period during which the Offer will remain open for acceptance (being the Offer Period) to 5:00pm (Sydney time) on Monday 14 July 2025 (unless further extended or withdrawn in accordance with the Corporations Act);
- (b) replacing "7 July 2025" with "14 July 2025" in each place that the closing date of the Offer, or the end of the Offer Period, is referred to in the Bidder's Statement (including in the Acceptance Forms).

### 2 New date for giving notice as to the status of Conditions

In accordance with section 630(2)(b) of the Corporations Act, the Bidder gives notice that:

- (a) as a result of the extension of the Offer Period, the new date for giving notice as to the status of Conditions of the Offer as set out in section 3.10(g) of the Bidder's Statement, as required by section 630(2) of the Corporations Act, is Monday 7 July 2025 (subject to any further variation(s) in accordance with the Corporations Act). Accordingly, the reference to "30 June 2025" in all instances in the Bidder's Statement as the date for giving the notice on the status of the Conditions is replaced with "7 July 2025"; and
- (b) as at the date of this notice:
  - (i) the Offer (and each contract resulting from acceptance of the Offer) has not been freed from the Conditions in section 3.10 of the Bidder's Statement; and
  - (ii) so far as the Bidder knows, none of the Conditions in section 3.10 of the Bidder's Statement has been fulfilled at the time of giving this notice,

and, accordingly, the Offer remains subject to the Conditions.

### 3 Lodgement with ASIC

A copy of this notice was lodged with the ASIC on 30 June 2025. ASIC takes no responsibility for the consents of this notice.

### 4 Approval

This notice has been approved by a resolution passed by the sole director of the Bidder. Except for the above variations, the terms of the Offer remain the same.

Date: 30 June 2025

Signed for and on behalf of the Bidder.



William Whitney George  
Director

**Rhinomed Health Corporation**